Table 2. Treatment response to combined immunotherapy with ipilimumab and pembrolizumab in cutaneous and uveal melanoma.
Best Response, N (%) | Cutaneous Melanoma (N = 24) | Uveal Melanoma (N = 9) |
---|---|---|
PD | 8 (33) | 4 (44) |
SD | 7 (29) | 5 (56) |
PR | 7 (29) | 0 (0) |
CR | 2 (8) | 0 (0) |
Abbreviations: PD = progressive disease, SD = stable disease, PR = partial response, CR = complete response.